Skip to main content Accessibility help
×
Home

Epidemiology of Vancomycin-Resistant Enterococci with Reduced Susceptibility to Daptomycin

  • Theresa Judge (a1), Jason M. Pogue (a1), Dror Marchaim (a2), Kevin Ho (a2), Srinivasa Kamatam (a2), Shakila Parveen (a2), Namita Tiwari (a2), Priyanka Nanjireddy (a2), Suchitha Bheemreddy (a2), Caitlin Biedron (a2), Sagar Mallikethi Lepakshi Reddy (a2), Vijaykumar Khammam (a2), Indu K. Chalana (a2), Rajachendra Shekher Tumma (a2), Vicki Collins (a2), Adnan Yousuf (a2), Paul R. Lephart (a3), Emily T. Martin (a4), Michael J. Rybak (a2) (a5), Keith S. Kaye (a2) and Kayoko Hayakawa (a2)...

Abstract

A retrospective case–case control study was conducted, including 60 cases with daptomycin-nonsusceptible vancomycin-resistant enterococci (DNS-VRE) matched to cases with daptomycin-susceptible VRE and to uninfected controls (1:1:3 ratio). Immunosuppression, presence of comorbid conditions, and prior exposure to antimicrobials were independent predictors of DNS-VRE, although prior daptomycin exposure occurred rarely. In summary, a case–case control study identified independent risk factors for the isolation of DNS-VRE: immunosuppression, multiple comorbid conditions, and prior exposures to cephalosporines and metronidazole.

Copyright

Corresponding author

Harper University Hospital, 3990 John R Street, Detroit, MI 48084 (kayokohayakawa@gmail.com)

References

Hide All
1. Canton, R, Ruiz-Garbajosa, P, Chaves, RL, Johnson, AP. A potential role for daptomycin in enterococcal infections: what is the evidence? J Antimicrob Chemother 2010;65:11261136.
2. Kelesidis, T, Humphries, R, Uslan, DZ, Pegues, DA. Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians. Clin Infect Dis 2011;52:228234.
3. Charlson, ME, Pompei, P, Ales, KL, MacKenzie, CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373383.
4. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobia Susceptibility Testing: Nineteenth Informational Supplement. Wayne, PA: CLSI; 2009. CLSI document M100-S19.
5. Kamboj, M, Cohen, N, Gilhuley, K, Babady, NE, Seo, SK, Sepkowitz, KA. Emergence of daptomycin-resistant VRE: experience of a single institution. Infect Control Hosp Epidemiol 2011;32:391394.
6. Munoz-Price, LS, Lolans, K, Quinn, JP. Emergence of resistance to daptomycin during treatment of vancomycin-resistant Enterococcus faecalis infection. Clin Infect Dis 2005;41:565566.
7. Arias, CA, Panesso, D, McGrath, DM, et al. Genetic basis for in vivo daptomycin resistance in enterococci. N Engl J Med 2011;365:892900.
8. Dade, Behring. MicroScan Dried Gram Positive Panels 2011–04 Enterococcus faecium with Reduced Susceptibility to Daptomycin. Technical Support Bulletin 182. Sacramento, CA: Dade Behring, 2011.
9. Palavecino, EL, Schoppe, CH. Discrepancies between daptomycin susceptibility results by MicroScan panel PC29 and by E test in S. aureus and enterococci. The 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Chicago; 2011.

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed